Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Melanoma 2

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × sitravatinib × Dermatologic × Clear all
NCT05542342 2026-06-01

SITISVEAL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed
16 enrolled 14 charts
Dermatologic

Melanoma

NCT05104801 2021-11-04

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
37 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡